ITGAM and melanoma: Administration of an anti‐GPNMB monoclonal Ab (mAb) or completely GPNMB knockout on CD11b+Gr1+ cells, could abrogate CD11b+Gr1+ cells expansion, impact their suppressor function on T cells, and diminish melanoma development in vivo.35